mp.weixin.qq.com·· 11 hours agoPickScore75
Johnson & Johnson's Teclistamab Wins New China Indication for Relapsed or Refractory Multiple Myeloma After at Least One Prior Line
In brief
Johnson & Johnson announced that the NMPA has approved a new indication for Tecvayli (teclistamab injection) for relapsed or refractory multiple myeloma in patients who have received at least one prior line of therapy, including an anti-CD38 monoclonal antibody and lenalidomide.
Why it matters
The source gives specific HR, CI and ≥CR rates for the MajesTEC-9 PFS and OS endpoints, allowing direct comparison with other same-target bispecifics in second-line multiple myeloma.
Source: mp.weixin.qq.com · mp.weixin.qq.com